Lipocine Signs TLANDO Franchise License Deal With Verity Pharma
I'm PortAI, I can summarize articles.
Lipocine Inc. has signed an exclusive license agreement with Verity Pharmaceuticals to market TLANDO, an FDA-approved testosterone replacement therapy, in the U.S. and potentially in Canada. Lipocine will receive a payment of $2.5 million upon signing, along with a $11 million license fee. Additionally, Lipocine will receive milestone and royalty payments totaling $259 million. The company's stock is currently gaining 0.52 percent in pre-market activity.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments